Independent. Senior-led. Built on HTA experience.

“We needed a submission that would meet the committee's evidence standards on a tight timeline. The economic case was clear, the clinical arguments were grounded in the evidence, and clarification questions were answered quickly. The appraisal reached a positive recommendation.”

“Our NCPE rapid review had a short window and several open questions on the model. Evidaxia identified the key issues quickly and delivered a clean, fully documented submission. The process went more smoothly than I expected.”

“Joint clinical assessment is new territory for most teams, ours included. The PICO scoping was thoughtful, the indirect treatment comparisons and network meta-analysis were transparent, and the dossier was ready when we needed it. We went into the process with confidence.”

“We handed over a global model and got back a Canadian adaptation for CDA-AMC that was easy to audit and easy to explain to payers. Assumptions were documented, every change was traceable, and questions got direct answers.”

“The SLR update was delivered on time, with search and screening records organised well enough to reuse for the next update. Communication was clear throughout. Exactly what we needed.”

“The pricing analysis helped us decide where to focus and what to expect from international reference pricing. It gave the team a clear view of the trade-offs rather than a long list of options.”

“Having someone in the room who understands both how HTA bodies think and the economics behind their decisions made the advisory board far more useful. The advice was practical, and it changed how we planned our evidence generation.”

“The evaluation was rigorous and, just as importantly, readable. The findings fed directly into our donor reporting and shaped the next phase of the programme.”